Antibiotic resistance · people (any age) with active trachoma
Oral azithromycin led to lower antibiotic resistance Proportion of samples showing evidence of… compared with control; GRADE not reported.
1 finding from 1 review
Antibiotic resistance · people (any age) with active trachoma
The review found no eligible studies for this question.
1 finding from 1 review
Antibiotics for trachoma 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Need for additional antibiotics: participants needing extra IV antibiotics · adults and children with cystic fibrosis
1 finding from 1 review
Need for additional antibiotic therapy · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for additional antibiotic therapy · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for additional antibiotic therapy · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: any antibiotic‐related adverse event leading to discontinuation of therapy · women with PID
Regimens containing macrolides (azithromycin) showed no clear difference in adverse events: any antibiotic‐related adverse event leading to… compared with regimens containing tetracycline (doxycycline) (low certainty).
1 finding from 1 review
RR 0.71 [0.38, 1.34]
Studies not reported
Low
Number experiencing adverse effects · children with cystic fibrosis and a new culture positive for P aeruginosa
Inhaled tobramycin (TNS) plus oral azithromycin showed no clear difference in adverse effects of antibiotics: number of participants experiencing… compared with TNS plus oral placebo (moderate certainty).
1 finding from 1 review
Clinical cure (bacteriological per protocol analysis) · group A streptococcal pharyngitis
It is very uncertain whether azithromycin changes clinical cure (bacteriological per protocol analysis) compared with amoxicillin (very low certainty).
1 finding from 1 review
Relapse · group A streptococcal pharyngitis
It is very uncertain whether azithromycin changes relapse (ITT analysis) compared with amoxicillin (very low certainty).
1 finding from 1 review
Relapse (bacteriological per protocol analysis) · group A streptococcal pharyngitis
It is very uncertain whether azithromycin changes relapse (bacteriological per protocol analysis) compared with amoxicillin (very low certainty).
1 finding from 1 review
Adverse events (ITT analysis) · group A streptococcal pharyngitis
It is very uncertain whether azithromycin changes adverse events (ITT analysis) compared with amoxicillin (very low certainty).
1 finding from 1 review
Clinical cure · group A streptococcal pharyngitis
It is very uncertain whether azithromycin changes clinical cure (ITT analysis) compared with amoxicillin (very low certainty).
1 finding from 1 review
All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (high certainty).
1 finding from 1 review
Resolution of symptoms · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
Azithromycin showed no clear difference in all initial symptoms resolved (asymptomatic) at day 14 compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
Time to resolution · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Quality of life at longest · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Adverse events during treatment period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Serious adverse events during the study period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Arrhythmias · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review